NCT00688766 / 2008-002396-28: Study Evaluating IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) Following Failure of at Least Imatinib and Sunitinib |
|
|
| Terminated | 3 | 47 | US | retaspimycin hydrochloride (IPI-504), placebo, Best supportive care | Infinity Pharmaceuticals, Inc., MedImmune LLC, AstraZeneca | Gastrointestinal Stromal Tumors | 05/09 | 05/09 | | |